Halozyme Therapeutics, Inc. (HALO) stock analysis

HALO · Halozyme Therapeutics, Inc.

Latest recorded price: USD 96.50

Model-estimated fair value: USD 120.20. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Biotechnology

At $96.50, HALO trades 19.7% below the model's base-case value of $120.20. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $85.46 in the conservative case and $162.14 in the optimistic case, with a valuation confidence score of 55/100. Fiscal 2025 figures: revenue growth 28.4%, free cash flow margin 46.2%, ROIC 16.3%. The model does not flag any risk signals for this company.

Similar companies in Healthcare